Evidence map›Paper›PMID 36769101›Full record

ArticleInternational journal of molecular sciences2023

Targeted Therapy for Glomerulonephritis Using Arterial Delivery of Encapsulated Etanercept.

Natalia A Shushunova, Oksana A Mayorova, Ekaterina S Prikhozhdenko, Olga A Goryacheva, Oleg A Kulikov, Valentina O Plastun, Olga I Gusliakova, Albert R Muslimov, Olga A Inozemtseva, Nikolay A Pyataev and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Natalia A ShushunovaScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.
Oksana A MayorovaScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.ORCID 0000-0002-6440-3947
Ekaterina S PrikhozhdenkoScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.ORCID 0000-0003-2700-168X
Olga A GoryachevaScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.ORCID 0000-0002-0910-7694
Oleg A KulikovInstitute of Medicine, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Str., 430005 Saransk, Russia.ORCID 0000-0002-0739-3981
Valentina O PlastunScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.
Olga I GusliakovaScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.ORCID 0000-0001-8387-0711
Albert R MuslimovScientific Center for Translational Medicine, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sirius, Russia.
Olga A InozemtsevaScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.
Nikolay A PyataevInstitute of Medicine, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Str., 430005 Saransk, Russia.
Alexander A ShirokovScience Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.ORCID 0000-0003-4321-735X
Dmitry A GorinCenter for Photonic Science and Engineering, Skolkovo Institute of Science and Technology, Bolshoy Boulevard 30, 121205 Moscow, Russia.
Gleb B SukhorukovA.V. Zelmann Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Bolshoy Boulevard 30, 121205 Moscow, Russia.
Olga A SindeevaA.V. Zelmann Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Bolshoy Boulevard 30, 121205 Moscow, Russia.ORCID 0000-0002-5288-4157

Funding

Russian Science Foundation 19-75-10043
6 · The paper itself

Abstract

Complex immunosuppressive therapy is prescribed in medical practice to patients with glomerulonephritis to help them overcome symptoms and prevent chronic renal failure. Such an approach requires long-term systemic administration of strong medications, which causes severe side effects. This work shows the efficiency of polymer capsule accumulation (2.8 ± 0.4 µm) containing labeled etanercept (100 μg per dose) in the kidneys of mice. The comparison of injection into the renal artery and tail vein shows the significant superiority of the intra-arterial administration strategy. The etanercept retention rate of 18% and 8% ID in kidneys was found 1 min and 1 h after injection, respectively. The capsules were predominantly localized in the glomeruli after injection in mice using a model of acute glomerulonephritis. Histological analysis confirmed a significant therapeutic effect only in animals with intra-arterial administration of microcapsules with etanercept. The proposed strategy combines endovascular surgery and the use of polymer microcapsules containing a high molecular weight drug that can be successfully applied to treat a wide range of kidney diseases associated with glomerular pathology.

Indexed as

GlomerulonephritisAnimalsCapsulesEtanerceptKidneyKidney GlomerulusMiceCapsulesEtanerceptacute glomerulonephritisEnbreletanerceptFreund’s complete adjuvantintra-arterial injectionnephritispolyelectrolyte microcapsulestargeted drug delivery

Identifiers

PMID36769101
PMCPMC9917155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.